Clinical criteria for cisplatin eligibility

Patients who are medically fit and eligible for cisplatin-based therapy meet all of the criteria below:

ECOG performance status <2 or a Karnofsky performance status >70%

Creatinine clearance ≥60 mL/min

No significant hearing loss (measured at audiometry of 25 dB at 2 contiguous frequencies)

Grade <2 peripheral neuropathy (ie, sensory alteration or paresthesia, including tingling, but not interfering with activities of daily living)

No clinical evidence of NYHA class III or greater heart failure

ECOG: Eastern Cooperative Oncology Group; NYHA: New York Heart Association.

Reference:

Galsky MD, Hahn NM, Rosenberg J, et al. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol 2011; 12:211.

Graphic 143615 Version 1.0